Table 2.

Generalized Estimating Equations Model with undermentioned factors as potential predictors of the treatment outcome based on the NIH Mouth Staging Score during the 12-week study period. Scores of the NIH Mouth Staging Score range from 0 to 3, representing no symptoms (0) and severe symptoms with limitation of oral intake (3), respectively. N = 53

	Ba	p
Gender 0 = men, 1 = women	0.38	0.005*
Age	− 0.01	0.35
Ruxolitinib dose	− 0.01	0.65
Immunosuppressive therapy during research period 0 = no, 1 = yes	− 0.46	0.02*
Topical treatment during research period 0 = no, 1 = yes	0.15	0.25
Visit	− 0.41	< 0.001*
Score at baseline	0.03	0.71

^a B represents the multiplier factor on the NIH Mouth Staging Score. * Statistically significant (p < 0.05)